PharmaShots | Incisive News in 3 Shots

Subscribe Now

Alydia Health

AbbVie Reports the US FDA's Acceptance of NDA for Atogepant as a Preventive Treatment for Migraine

AbbVie Reports the US FDA's Acceptance of NDA for Atogepant as a Preventive Treatment for Migraine

March 31, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us